Entyvio linked with lower risk for non-infectious adverse events in Crohn’s

Entyvio yielded a lower risk for non-infectious serious adverse events than TNF antagonist therapy in Crohn’s disease, according to a study published in Alimentary Pharmacology and Therapeutics.However, the same was not true regarding serious infections. Further, there was no significant difference in achievement of disease remission between Entyvio (vedolizumab, Takeda) and TNF antagonist therapy.“Post-hoc secondary analyses observed a significant difference between vedolizumab and TNF-antagonist therapy for the risk of non-infectious adverse events specifically, which remainedRead More

Share on facebook
Share on twitter
Share on linkedin